Benzinga · Jul 31, 2026
Profusa Enters Option Agreement To Buy G3 Vision Labs And Affiliates; Has Right To Buy 100% Of G3 Vision Labs
-SEC Filing
PF
NASDAQ · PFSA
Profusa, Inc. Common Stock
Healthcare · Medical - Equipment & Services
$0.97
Down-$0.05 (-5.14%)
Updated Aug 13, 2026, 6:33 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 7.48M
- P/E ratio
- -0.14
- Dividend yield
- 0.00%
- 52-week range
- $0.10 – $3.30
- Volume
- 31.37K
- Avg. volume
- 12.57M
Price performance
PFSA price history
1M range · 21 trading sessions · Daily adjusted prices
PFSA closed at $0.97 after 21 trading sessions, down 48.94% for the selected period.
- Last close
- $0.97
- Period change
- -48.94%
- Period low
- $0.94
- Period high
- $2.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $0.97 | $0.97 | $0.95 | $0.965 | 31.37K |
| Aug 11, 2026 | $0.95 | $0.9999 | $0.94 | $0.985 | 48.16K |
| Aug 10, 2026 | $0.958 | $0.9843 | $0.9224 | $0.939 | 38.83K |
| Aug 7, 2026 | $0.9199 | $0.9799 | $0.911 | $0.9628 | 51.08K |
| Aug 6, 2026 | $0.9127 | $1.00 | $0.9053 | $0.939 | 95.31K |
| Aug 5, 2026 | $0.96 | $0.962 | $0.892 | $0.9409 | 67.42K |
| Aug 4, 2026 | $0.94 | $1.01 | $0.9211 | $0.98 | 100.5K |
| Aug 3, 2026 | $0.9811 | $1.03 | $0.8801 | $0.9626 | 314.04K |
| Jul 31, 2026 | $1.04 | $1.11 | $0.98 | $1.06 | 1.83M |
| Jul 30, 2026 | $1.00 | $1.11 | $0.911 | $1.06 | 130.17K |
| Jul 29, 2026 | $0.98 | $1.05 | $0.965 | $0.991 | 129.99K |
| Jul 28, 2026 | $1.02 | $1.10 | $0.8608 | $1.04 | 585.07K |
| Jul 27, 2026 | $1.28 | $1.38 | $0.9404 | $1.22 | 7.97M |
| Jul 24, 2026 | $1.76 | $1.797 | $1.60 | $1.71 | 25.96K |
| Jul 23, 2026 | $1.82 | $1.85 | $1.70 | $1.76 | 39.23K |
| Jul 22, 2026 | $1.95 | $1.98 | $1.8019 | $1.90 | 97.13K |
| Jul 21, 2026 | $2.03 | $2.45 | $1.85 | $2.00 | 590.12K |
| Jul 20, 2026 | $1.77 | $2.04 | $1.69 | $1.95 | 178.43K |
| Jul 17, 2026 | $1.80 | $1.90 | $1.69 | $1.73 | 61.82K |
| Jul 16, 2026 | $1.86 | $1.9699 | $1.84 | $1.86 | 88.32K |
| Jul 15, 2026 | $2.02 | $2.025 | $1.80 | $1.89 | 172.02K |
Latest PFSA news
The latest Smart Investors Daily articles mentioning PFSA.
Stock researchCompany · Overview
PFSA research
Overview
Company profile and research snapshot.
Company profile
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jul 27, 2026
Why Is Profusa Stock Falling Monday?
PFSA stock fell 18.5% in premarket trading after Profusa named a new CEO and signed a deal to acquire a $111M diagnostics firm.
Benzinga · Jul 27, 2026
Profusa To Merge With Privately Held, Commercial-Stage Health Diagnostics And Toxicology Testing Company; Profusa To Issue 19.99% Stake to The Company And Will Issue Convertible Prefs; Combined Entity Operate As Public Diagnostics Firm
Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers
Benzinga · Jul 7, 2026
Profusa Files Resale Prospectus For Offer And Resale From Time To Time Of Up To 7,170,891 Shares Of Common Stock By Selling Stockholders
PROFUSA, INC. 7,170,891 Shares of Common Stock by the Selling Stockholders This prospectus supplement amends and supplements certain information contained in the prospectus dated May 4, 2026 (the "Prospectus"),
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
